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Abstract
Objective: We aimed to investigate the association between baseline plasma fatty acids profile and the risk of future major
cardiovascular events in patients with a history of ischaemic heart disease or ischemic stroke.
Methods: Baseline plasma fatty acids as well as established cardiovascular risk factors were measured in 2,263 patients
enrolled in the SUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids randomized controlled
trial. Incident major cardiovascular, cardiac and cerebrovascular events were ascertained during the 4.7 years of follow up.
Hazard ratios were obtained from Cox proportional hazards models after adjustment for cardiovascular risk factors.
Results: During the follow-up, 154, 379 and 84 patients had major cardiovascular, cardiac and cerebrovascular events
respectively. Upon adjustment for gender, initial event, baseline age and BMI, the risk of developing a major cardiovascular
event decreased significantly in successive quartiles of arachidonic acid (Ptrend,0.002), total omega 3 polyunsaturated fatty
acids (Ptrend,0.03), docosapentaenoic acid (Ptrend,0.019), docosahexaenoic acid (Ptrend,0.004), eicosapentaenoic acid +
docosahexaenoic acid (Ptrend,0.03) and eicosapentaenoic acid + docosapentaenoic acid + docosahexaenoic acid
(Ptrend,0.02). This inverse association was borderline significant with increased quartiles of stearidonic acid (Ptrend,0.06).
In the full model, only stearidonic acid remained inversely associated with the risk of developing a major cardiovascular
event (Ptrend,0.035), a cardiac event (Ptrend,0.016) or a cerebrovascular event (Ptrend,0.014), while arachidonic acid was
inversely associated with the risk a cerebrovascular event (Ptrend,0.033).
Conclusion: The inverse association of long chain omega 3 polyunsaturated fatty acids with recurrence of Cardiovascular
diseases was mainly driven by well-known cardiovascular risk factors.
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Introduction
The incidence of cardiovascular diseases (CVD) is suggested to
be modulated by dietary fatty acid composition, ie saturated fatty
acids (SFA) increasing and polyunsaturated fatty acids (PUFA)
decreasing serum cholesterol levels and risk of CVD [1]. Some
fatty acids influence the incidence of CVD through triglyceride
accumulation, inflammation, vasodilation, or platelet aggregation
[2]. SFA and monounsaturated fatty acids (MUFA) are the main
components of triglycerides, although mechanisms linking the
relationships between CVD and individual fatty acids remain
uncertain.
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Based on these hypotheses, several epidemiological studies have
examined associations between several fatty acids and stroke,
arrhythmia and coronary disease risk factors. Some prospective
epidemiologic studies have reported a significant association
between fish intake or n–3 fatty acids derived from fish oil and a
lower risk of CVD [1,3–6]. However, randomized controlled trials
and meta-analyses have yielded inconsistent results [1,7–12]. A
number of hypotheses could explain these discrepancies. First, the
changes in tissue lipid composition as well as the beneficial anti-
inflammatory and anti-atherogenic properties of a diet high in n–3
fatty acids require a long time to express. Thus, studies and meta-
analyses conducted for less than one year may be unable to detect
a clinical benefit [12]. Second, supplements given as part of dietary
interventions have a strictly controlled dose and content unlike
others; therefore, while compliance with a ‘‘self-administered’’
dietary supplement may be greater than that in dietary interven-
tions, it is not clear whether both supplementations have similar
effects. Many systematic reviews have included both dietary
interventions and dietary supplements; this is likely to lead to
significant heterogeneity [11]. Equally important is the fact that
different formulations with different dosages have been used. As a-
linolenic acid is a plant-based n–3 polyunsaturated fatty acid
(PUFA) that is poorly converted (less than 5%) to eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), it is therefore
Table 1. Baseline sociodemographic, clinical and biologic characteristics of SU. FOL.OM3 participants without and with major
events, cardiac and cerebrovascular events at the end of the follow-up.
Characteristics No events Major events P* Cardiac events P{ Cerebrovascular events P`
N 1717 154 379 85
EPA + DPA
supplementation, n (%)
1717 (50.9) 78 (50.6) 0.95 185 (48.8) 0.46 40 (47.1) 0.49
Age, years 61.468.9 63.669.5 0.006 62.369.3 0.12 66.068.5 ,0.0001
Men, n (%) 1375 (80.1%) 124 (80.5%) 0.67 315 (83.1%) 0.13 69 (81.2%) 0.43
BMI, kg/m2 27.564.0 27.864.4 0.27 27.764.0 0.48 28.064.1 0.19
SBP, mm Hg 133.1621.3 136.8623.4 0.24 134.1622.0 0.78 141.5623.9 0.03
DBP, mm Hg 83.4612.2 83.4612.5 0.87 82.5612.5 0.16 85.5612.2 0.20
MAP, mm Hg 99.9614.5 101.2615.3 0.64 99.7614.8 0.51 104.2615.3 0.08
Total energy intake,
kcal/day1
24456991 23436856 0.50 24706941 0.52 22996591 0.61
Total fibre intake, g/day1 24.6610.7 23.269.8 0.13 25.2610.6 0.42 24.069.3 0.52
Total fish intake, g/day1 62.3663.9 51.6639.6 0.07 63.7670.8 0.67 51.1644.4 0.20
Fat fish intake, g/day1 19.7626.9 17.3621.4 0.40 18.9622.0 0.65 17.0620.3 0.55
Total cholesterol, mmol/L 4.6061.05 4.7861.03 0.04 4.6861.09 0.24 4.8861.10 0.03
HDL-cholesterol, mmol/L 1.2060.30 1.2160.32 0.57 1.1960.32 0.22 1.2460.34 0.85
LDL-cholesterol, mmol/L 2.7660.84 2.8860.86 0.11 2.8460.90 0.19 2.9960.91 0.03
Triglycerides, mmol/L 1.4060.77 1.6061.00 0.004 1.5060.96 0.04 1.4660.88 0.36
Glycaemia, mmol/L 5.8161.56 6.1962.09 0.009 6.1262.09 0.001 5.9461.80 0.51
Smoking status, n (%) 0.007 0.23 0.002
Current smoker 181 (10.7) 25 (16.3) 36 (9.5) 14 (16.7)
Former smoker 1040 (61.5) 92 (60.1) 249 (65.7) 52 (61.9)
Never smoked 471 (27.8) 36 (23.5) 94 (24.8) 18 (21.4)
Alcohol intake, g/day 0.002 0.16 0.007
.10 833 (48.5) 71 (46.1) 181 (47.8) 40 (47.1)
0.5–10 468 (27.3) 27 (17.5) 88 (23.2) 13 (15.3)
,0.5 156 (9.1) 19 (12.3) 41 (10.8) 11 (12.9)
Missing information 260 (15.1) 37 (24.0) 69 (18.2) 21 (24.7)
Inclusion criteria, n (%) 0.009 ,0.0001 ,0.0001
Stroke 444 (25.9) 59 (38.3) 55 (14.5) 52 (61.2)
Myocardial infarction 773 (45.0) 63 (40.9) 198 (52.2) 18 (21.2)
Unstable angina 500 (29.1) 32 (20.8) 126 (33.2) 15 (17.6)
Diabetes 0.004 0.002 0.03
Yes 278 (16.2%) 40 (26%) 87 (23.0%) 22 (25.9%)
No 1439 (83.8%) 114 (74%) 292 (77.0%) 63 (74.1%)
Data are frequencies (percentages) or mean 6 SD.
P values are for the comparison of *major, {cardiac and `cerebrovascular events with participants without events at the end of the study.
1Food frequency questionnaires were filled only by 85% of the study participants, and these values are obtained from subjects for which the information was available.
doi:10.1371/journal.pone.0092548.t001
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unlikely that it would have the cardioprotective effects of fish oil
[13,14].
Although several studies have examined the relationship
between PUFA intake and the incidence of CVD, no clear
consensus yet exists regarding the effects of various fatty acid
compositions, including that of PUFA on the development of
CVD [7,8,15]. This may be at least partly due to the fact that
dietary intake is difficult to quantify precisely due to self-reporting
bias, difficulties in evaluating consumed portion sizes, lack of
information about cooking methods, and lack of precision as
regards food composition tables, particularly for processed food
[16,17]. Usual methods of dietary assessment such as food
frequency questionnaires, diet history or repeated 24-h recall/
records are used in large epidemiological studies to assess fatty
acids intake, yet these are subject to the above limitations, as well
as to errors in recall [16,17].
We recently completed the SU.FOL.OM3 study, a double
blind, randomized, placebo controlled secondary prevention trial
which aimed to investigate whether dietary supplementation with
B vitamins or n–3 fatty acids, or both, could prevent subsequent
major cardiovascular events in patients with a history of CVD
[18]. Supplementation with n-3 fatty acids did not have any
significant effects on major vascular events. In the present ancillary
analysis of the SU.FOL.OM3 trial, we explored the association
between baseline plasma fatty acids (PFA) and the risk of
secondary cardiovascular events in this population with recent
medical history of CVD.
Methods
The supporting CONSORT checklist is available as supporting
information; see Checklist S1.
Ethics statement
The protocol was approved by the ethic commitee ‘‘Comite´
Consultatif pour la Protection des Personnes se preˆtant a` la
Recherche Biome´dicale’’ (CCPPRB nu 1933) of Paris-Cochin
Hospital, and the data protection board ‘‘Commission Nationale
de l’Informatique et des Liberte´s’’ (CNIL nu 901230). Participants
provided their written informed consent to participate in this
study. The current analyses included 2,263 subjects for whom
baseline PFA were available.
Study population
Details concerning study methods and participant characteris-
tics were reported elsewhere [18]. In brief, 2,501 participants 45–
80 years (1,987 men and 514 women) with a prior history of an
acute coronary or cerebral ischemic event occurring within 1 to 12
months were recruited via a network of 417 cardiologists,
neurologists or other physicians throughout France. They were
Table 2. Baseline plasma lipid profile of SU.FOL.OM3 participants without and with major events, cardiac and cerebrovascular
events at the end of the follow-up.
Plasma lipid profile No events Major events P* Cardiac events P{ Cerebrovascular events P`
N 1717 154 379 85
Total fatty acids, mmol/L 1056862677 1130262920 0.003 10756.3 0.24 11056.1 0.19
Total saturated FA 29.7162.89 29.9963.26 0.52 29.7462.97 0.99 29.7363.19 0.77
Palmitic acid (C 16:0) 22.2862.28 22.5562.47 0.31 22.3362.37 0.85 22.3862.34 0.90
Trans fatty acids 0.1460.10 0.1460.10 0.98 0.1460.11 0.79 0.1460.10 0.91
Total MUFA 25.8363.73 26.5163.71 0.10 25.8963.79 0.90 26.2163.67 0.97
Oleic acid (C 18:1 n – 9) 21.3063.03 21.7563.16 0.24 21.3863.18 0.72 21.3963.11 0.51
Total PUFA 44.1365.66 43.1865.64 0.16 44.0565.65 0.96 43.7365.46 0.90
Total n-6 PUFA 38.7165.31 38.0765.31 0.44 38.7565.47 0.75 38.5965.01 0.59
Linoleic acid (C 18:2 n – 6) 27.2864.69 27.0764.57 0.95 27.5264.74 0.19 27.7064.65 0.16
Dihomo-U-linolenic acid
(C20:3 n – 6)
1.5960.34 1.6260.40 0.30 1.5860.36 0.64 1.6660.44 0.058
Arachidonic acid
(C 20:4 n – 6)
8.7961.96 8.3462.06 0.04 8.6062.15 0.06 8.2261.99 0.04
Total n-3 PUFA 5.4261.84 5.1161.83 0.04 5.3061.89 0.29 5.1461.79 0.24
a-linolenic acid
(C 18:3 n – 3)
0.6160.27 0.5960.24 0.44 0.6260.27 0.17 0.5760.20 0.41
Stearidonic acid acid
(C 18:4 n – 3)
0.0460.04 0.0360.03 0.006 0.0360.04 0.007 0.0260.03 0.005
EPA (C 20:5 n – 3) 1.4260.87 1.3360.85 0.16 1.3860.90 0.37 1.3360.88 0.42
DPA (C 22:5 n – 3) 0.6060.15 0.5760.15 0.03 0.5960.17 0.38 0.5860.14 0.10
DHA (C 22:6 n – 3) 2.7560.92 2.5860.93 0.04 2.6860.91 0.15 2.6360.88 0.33
EPA + DHA 4.1761.68 3.9161.67 0.06 4.0661.70 0.21 3.9661.66 0.34
EPA + DPA + DHA 4.7761.76 4.4861.77 0.05 4.6561.81 0.21 4.5461.74 0.30
N – 3/n – 6 ratio 0.1460.05 0.1460.05 0.15 0.1460.06 0.37 0.1360.05 0.18
All values are expressed as percentage of total plasma fatty acids, except for total plasma fatty acids.
P values are for the comparison of *major, {cardiac and `cerebrovascular events with participants without events at the end of the study, after adjusting for total energy
intake.
doi:10.1371/journal.pone.0092548.t002
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Table 3. Multivariate hazard ratios (95% confidence intervals) showing the associations between baseline plasma lipid profile and
incident major events in the SU.FOL.OM3 study.
Plasma lipid profile HR Q1 HR Q2 HR Q3 HR Q4 P P for trend
Total fatty acids
Model 1 1.0 1.32 (0.80–2.17) 1.54 (0.95–2.50) 1.54 (1.08–2.81) 0.13 0.018
Model 2 1.0 1.18 (0.62–2.25) 1.37 (0.65–2.89) 1.06 (0.35–3.25) 0.68 0.15
Total SFA
Model 1 1.0 0.56 (0.35–0.91) 0.81 (0.52–1.25) 0.97 (0.64–1.48) 0.08 0.75
Model 2 1.0 0.58 (0.33–1.01) 0.82 (0.49–1.37) 0.71 (0.39–1.30) 0.27 0.42
Palmitic acid (C 16:0)
Model 1 1.0 0.58 (0.36–0.94) 0.88 (0.57–1.35) 0.94 (0.61–1.45) 0.14 0.80
Model 2 1.0 0.48 (0.27–0.86) 0.82 (0.49–1.37) 0.63 (0.34–1.17) 0.077 0.33
Trans fatty acids
Model 1 1.0 0.99 (0.64–1.54) 0.95 (0.61–1.50) 0.92 (0.58–1.45) 0.98 0.69
Model 2 1.0 0.95 (0.57–1.58) 1.03 (0.61–1.75) 0.90 (0.52–1.56) 0.96 0.80
Total MUFA
Model 1 1.0 1.74 (1.07–2.83) 1.52 (0.92–2.50) 1.88 (1.16–3.07) 0.066 0.029
Model 2 1.0 1.61 (0.91–2.84) 1.50 (0.83–2.71) 1.55 (0.79–3.04) 0.40 0.25
Oleic acid (C 18:1 n – 9)
Model 1 1.0 1.06 (0.66–1.70) 1.28 (0.82–2.01) 1.29 (0.82–2.03) 0.59 0.19
Model 2 1.0 1.12 (0.65–1.91) 1.04 (0.60–1.82) 0.94 (0.49–1.81) 0.94 0.834
Total PUFA
Model 1 1.0 0.79 (0.51–1.21) 0.83 (0.54–1.27) 0.64 (0.41–1.02) 0.31 0.089
Model 2 1.0 1.25 (0.71–2.21) 1.11 (0.59–2.09) 1.05 (0.53–2.08) 0.85 0.93
Total n-6 PUFA
Model 1 1.0 0.91 (0.59–1.41) 0.87 (0.56–1.34) 0.71 (0.45–1.13) 0.53 0.15
Model 2 1.0 0.95 (0.54–1.67) 0.99 (0.54–1.80) 0.93 (0.49–1.77) 0.99 0.87
Linoleic acid (C 18:2 n – 6)
Model 1 1.0 0.93 (0.58–1.48) 1.19 (0.77–1.85) 1.20 (0.77–1.88) 0.62 0.53
Model 2 1.0 0.96 (0.55–1.67) 0.99 (0.58–1.69) 1.34 (0.80–2.25) 0.55 0.28
Dihomo-U-linolenic acid (C 20:3 n – 6)
Model 1 1.0 0.96 (0.61–1.51) 0.99 (0.64–1.59) 1.02 (0.65–1.61) 0.99 0.88
Model 2 1.0 1.15 (0.66–2.02) 1.32 (0.77–2.27) 1.43 (0.82–2.49) 0.61 0.18
Arachidonic acid (C 20:4 n – 6)
Model 1 1.0 0.75 (0.49–1.12) 0.62 (0.40–0.96) 0.51 (0.32–0.81) 0.023 0.002
Model 2 1.0 0.91 (0.55–1.52) 0.84 (0.49–1.44) 0.60 (0.32–1.12) 0.424 0.133
Total n-3 PUFA
Model 1 1.0 0.89 (0.59–1.35) 0.69 (0.44–1.07) 0.65 (0.41–1.03) 0.184 0.032
Model 2 1.0 1.46 (0.89–2.39) 0.85 (0.48–1.52) 0.83 (0.46–1.50) 0.103 0.253
a-linolenic acid (C 18:3 n – 3)
Model 1 1.0 0.94 (0.61–1.45) 0.91 (0.59–1.43) 0.92 (0.59–1.44) 0.976 0.682
Model 2 1.0 0.96 (0.58–1.60) 0.88 (0.52–1.51) 0.89 (0.52–1.53) 0.989 0.612
Stearidonic acid (C 18:4 n – 3)
Model 1 1.0 1.14 (0.76–1.71) 0.80 (0.53–1.23) 0.66 (0.40–1.09) 0.152 0.062
Model 2 1.0 0.93 (0.58–1.51) 0.72 (0.44–1.18) 0.56 (0.30–1.01) 0.206 0.035
EPA (C 20:5 n – 3)
Model 1 1.0 0.95 (0.62–1.45) 0.83 (0.54–1.29) 0.78 (0.49–1.23) 0.692 0.233
Model 2 1.0 1.35 (0.81–2.24) 1.06 (0.61–1.84) 0.87 (0.48–1.59) 0.436 0.540
DPA (C 22:5 n – 3)
Model 1 1.0 0.78 (0.52–1.17) 0.58 (0.37–0.91) 0.64 (0.40–1.00) 0.076 0.019
Model 2 1.0 0.86 (0.52–1.43) 0.77 (0.45–1.30) 0.77 (0.44–1.34) 0.739 0.298
Plasma FA and CV Risk in Secondary Prevention
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randomly assigned using a two-by-two factorial design, to receive
either 1) B-vitamins alone, 2) n-3 PUFA alone 3) both active
treatments or 4) both placebo treatments.
CVD ascertainment
Every six months, questionnaires were mailed to all participants
seeking information about any serious disease outcomes, compli-
ance with the assigned regimen, presence of cardiovascular risk
factors and adverse effects of the supplementation. A non-
mandatory visit was scheduled annually and participants who
were unable or unwilling to attend or who did not return the
questionnaire were interviewed by telephone by study physicians.
Family physicians also contacted the trial participants every six
months in order to seek information on any health events that may
have occurred. Two independent committees of cardiologists or
neurologists who were blinded to the treatment allocation
adjudicated all events. Participants were censored either on the
date of their first major event, the date of death, or, for those
without an event, at the end of follow-up on July 1, 2009. Three
composite endpoints were used to evaluate the association between
baseline PFA and cardiovascular events: 1) Major cardiovascular
events, which included non-fatal myocardial infarction, non-fatal
ischemic stroke or death from cardiovascular disease. 2) Cardiac
events, which included acute coronary syndrome without myo-
cardial infarction; resuscitation from sudden death; coronary
artery bypass surgery; coronary angioplasty; cardiac failure;
ventricular arrhythmia; supraventricular arrhythmia; cardiac
surgery of any kind and carotid surgery or caro0tid artery
angioplasty. 3) Cerebrovascular events, which included: ischemic
or haemorrhagic stroke and transient ischemic attack.
Assessment of PFA profile and data collected at baseline
Data on gender, age, smoking status, existing hypertension,
diabetes or dyslipidaemia, n-3 supplementation and medication
use were collected at baseline via a questionnaire. Dietary intake
(especially fish consumption) and alcohol consumption were
assessed using a Food Frequency Questionnaire. Body mass index
(BMI in kg/m2) was calculated from the standardized measure-
ments of height and weight. Blood pressure was recorded by
trained staff for each patient in the sitting position, after a 5-min
rest.
Venous blood samples were drawn after at least a 5-hour fast.
Measured biological parameters included cholesterol (total, LDL,
and HDL) and triglycerides (measured by enzymatic method with
the use of C8000 System Abbott, Rungis, France), fasting blood
glucose concentrations (enzymatic method) and total homocyste-
ine (measured by a competitive immunoassay with direct
chemiluminescence detection). Biological assessments were ob-
tained by standard methods at a centralized laboratory.
Total (free and esterified) fatty acids composition of plasma
lipids was determined by gas chromatography of the correspond-
ing methyl esters. Cleavage of the ester bonds of triglycerides and
cholesterol esters was performed by saponification. Specifically,
lipids were extracted from 150 mL aliquots of plasma with 8 mL
hexane: isopropanol (3:2, vol:vol) after the addition of heptade-
canoic acid as an internal standard. The fatty acids were
saponified with 1.0 mL NaOH in dry methanol at 100uC for
10 min and methylated with boron trifluoride 14% in methanol.
The methylated fatty acids were extracted with n-heptane and
quantified by gas chromatography with a flame ionisation detector
(6850 Agilent) using a capillary column (Quadrex 30 m length,
0.25 mm id, film thickness 0.25 mm, Alltech). The temperature
gradient was programmed at 50uC/min from 50uC to 140uC,
1.4uC/min from 140uC to 165uC and 10uC/min from 165uC to
245uC/min. Hydrogen was the carrier gas. The identification of
the individual methyl ester components was made by comparison
with a mixture of commercial standards. The results were
expressed as percentages of the total area of all fatty acid peaks.
Statistical analyses
Data are expressed as mean (6SD) or median (25th–75th
percentiles) and percentages (95% CI) as appropriate. Comparison
of baseline characteristics between participants with and without a
recurrent cardiovascular event relied on Student t tests, Wilcoxon
Rank tests or Chi square tests as appropriate. Cox proportional
hazards models were used to estimate the hazard ratios (HRs) and
95% 95% CI for major cardiovascular, cardiac and cerebrovas-
cular events by quartiles of each PFA as well as total saturated fatty
Table 3. Cont.
Plasma lipid profile HR Q1 HR Q2 HR Q3 HR Q4 P P for trend
DHA (C 22:6 n – 3)
Model 1 1.0 1.13 (0.75–1.69) 0.77 (0.50–1.20) 0.52 (0.32–0.86) 0.014 0.004
Model 2 1.0 1.29 (0.78–2.13) 0.99 (0.57–1.71) 0.63 (0.33–1.19) 0.124 0.120
EPA + DHA
Model 1 1.0 0.91 (0.60–1.38) 0.73 (0.47–1.14) 0.62 (0.39–0.99) 0.182 0.028
Model 2 1.0 1.35 (0.82–2.22) 1.02 (0.58–1.80) 0.79 (0.43–1.45) 0.285 0.348
EPA + DPA + DHA
Model 1 1.0 0.96 (0.64–1.45) 0.77 (0.50–1.19) 0.59 (0.36–0.95) 0.120 0.019
Model 2 1.0 1.56 (0.95–2.58) 1.17 (0.67–2.04) 0.76 (0.40–1.43) 0.07 0.303
N – 3/n – 6 ratio
Model 1 1.0 0.88 (0.57–1.36) 0.96 (0.63–1.48) 0.72 (0.45–1.16) 0.559 0.258
Model 2 1.0 1.13 (0.68–1.86) 1.03 (0.61–1.74) 0.75 (0.42–1.33) 0.553 0.341
Model 1: adjusted for age, BMI, initial event, gender.
Model 2: adjusted for covariates in Model 1 + treatment allocation group (both placebos, B vitamin and placebo of omega 3, omega 3 and placebo of B vitamins, omega
3 and B vitamins), tobacco smoking, alcohol consumption, systolic blood pressure, diabetes status, plasma cholesterol (HDL and LDL), triglycerides, total fatty acid
intake, n-3 supplementation and homocysteinemia.
doi:10.1371/journal.pone.0092548.t003
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Table 4. Multivariate hazard ratios (95% confidence intervals) showing the associations between baseline plasma lipid profile and
incident cardiac events in the SU.FOL.OM3 study.
Plasma lipid profile HR Q1 HR Q2 HR Q3 HR Q4 P P for trend
Total fatty acids
Model 1 1.0 1.12 (0.84–1.51) 1.23 (0.93–1.65) 1.23 (0.92–1.65) 0.452 0.130
Model 2 1.0 0.97 (0.67–1.42) 1.17 (0.73–1.87) 1.00 (0.47–2.13) 0.670 0.635
Total SFA
Model 1 1.0 0.82 (0.62–1.10) 0.90 (0.68–1.19) 0.89 (0.67–1.18) 0.623 0.540
Model 2 1.0 0.76 (0.55–1.06) 0.90 (0.65–1.24) 0.77 (0.53–1.12) 0.339 0.301
Palmitic acid (C 16:0)
Model 1 1.0 0.78 (0.59–1.05) 0.85 (0.64–1.13) 0.85 (0.64–1.13) 0.401 0.362
Model 2 1.0 0.70 (0.50–0.97) 0.81 (0.59–1.12) 0.76 (0.52–1.10) 0.183 0.209
Trans fatty acids
Model 1 1.0 0.99 (0.75–1.31) 1.00 (0.75–1.34) 0.98 (0.73–1.31) 0.998 0.905
Model 2 1.0 0.97 (0.71–1.33) 1.02 (0.74–1.40) 0.94 (0.67–1.31) 0.966 0.789
Total MUFA
Model 1 1.0 1.03 (0.77–1.37) 1.04 (0.78–1.39) 1.06 (0.79–1.41) 0.987 0.718
Model 2 1.0 1.02 (0.74–1.41) 1.05 (0.75–1.50) 1.13 (0.77–1.67) 0.932 0.535
Oleic acid (C 18:1 n – 9)
Model 1 1.0 1.07 (0.80–1.42) 0.98 (0.73–1.31) 0.98 (0.73–1.31) 0.929 0.762
Model 2 1.0 1.06 (0.77–1.46) 0.97 (0.69–1.37) 1.00 (0.67–1.48) 0.959 0.873
Total PUFA
Model 1 1.0 1.02 (0.77–1.35) 1.01 (0.76–1.34) 1.02 (0.76–1.36) 0.999 0.935
Model 2 1.0 1.10 (0.78–1.56) 1.08 (0.74–1.57) 1.10 (0.73–1.66) 0.957 0.710
Total n-6 PUFA
Model 1 1.0 1.05 (0.79–1.39) 0.89 (0.66–1.20) 1.10 (0.83–1.46) 0.539 0.787
Model 2 1.0 1.10 (0.78–1.56) 0.93 (0.64–1.36) 1.16 (0.78–1.70) 0.594 0.650
Linoleic acid (C 18:2 n – 6)
Model 1 1.0 0.75 (0.56–1.00) 0.84 (0.64–1.11) 0.84 (0.63–1.12) 0.261 0.357
Model 2 1.0 0.85 (0.62–1.18) 0.92 (0.68–1.26) 0.86 (0.62–1.20) 0.754 0.443
Dihomo-U-linolenic acid (C 20:3 n –
6)
Model 1 1.0 0.88 (0.67–1.17) 0.74 (0.55–0.98) 0.93 (0.70–1.23) 0.209 0.342
Model 2 1.0 0.90 (0.68–1.19) 0.73 (0.54–0.98) 0.94 (0.71–1.29) 0.196 0.402
Arachidonic acid (C 20:4 n – 6)
Model 1 1.0 0.87 (0.66–1.14) 0.80 (0.60–1.07) 0.86 (0.65–1.14) 0.467 0.227
Model 2 1.0 0.89 (0.64–1.23) 0.90 (0.64–1.26) 0.89 (0.62–1.28) 0.882 0.564
Total n-3 PUFA
Model 1 1.0 0.99 (0.75–1.31) 0.82 (0.61–1.09) 0.89 (0.67–1.18) 0.480 0.241
Model 2 1.0 1.21 (0.88–1.67) 0.99 (0.71–1.40) 0.98 (0.70–1.38) 0.508 0.644
a-linolenic acid (C 18:3 n – 3)
Model 1 1.0 0.87 (0.65–1.17) 0.96 (0.72–1.28) 1.15 (0.87–1.51) 0.287 0.253
Model 2 1.0 0.90 (0.64–1.26) 1.04 (0.75–1.46) 1.28 (0.93–1.77) 0.172 0.079
Stearidonic acid (C 18:4 n – 3)
Model 1 1.0 1.10 (0.84–1.44) 0.83 (0.64–1.08) 0.67 (0.49–0.92) 0.013 0.005
Model 2 1.0 0.94 (0.69–1.29) 0.86 (0.65–1.15) 0.63 (0.44–0.90) 0.084 0.016
EPA (C 20:5 n – 3)
Model 1 1.0 0.91 (0.70–1.20) 0.68 (0.51–0.91) 0.79 (0.59–1.04) 0.054 0.027
Model 2 1.0 1.05 (0.77–1.43) 0.82 (0.59–1.15) 0.80 (0.56–1.13) 0.292 0.102
DPA (C 22:5 n – 3)
Model 1 1.0 0.88 (0.66–1.15) 0.82 (0.62–1.08) 0.79 (0.60–1.06) 0.365 0.091
Model 2 1.0 0.84 (0.61–1.15) 0.87 (0.63–1.19) 0.78 (0.56–1.09) 0.494 0.177
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acids (SFA), trans fatty acids, monounsaturated fatty acids
(MUFA), PUFA, n-6 PUFA, n-3 PUFA, EPA + DPA, EPA +
DPA + DHA, and the n-3 PUFA to n-6 PUFA ratio. Associations
with baseline plasma fatty acids were adjusted for two sets of
potential confounding factors in model 1 (initial event, gender,
baseline age and BMI) and model 2 (model 1 + treatment
allocation group (both placebos, B vitamin and placebo of omega
3, omega 3 and placebo of B vitamins, omega 3 and B vitamins),
tobacco smoking, alcohol consumption, diabetes status, systolic
blood pressure, plasma cholesterol (total, HDL, LDL), n-3
supplementation, homocystinemia and total fatty acids intake).
Statistical analyses were performed using STATA 10. Statistical
tests were two-sided and p-values,0.05 were considered to be
statistically significant.
Results
During the follow-up, among the 2,263 participants with
available PFA, 154 developed a major cardiovascular event
(median time to event, 2.3 years, 25th–75th percentiles: 1.3–3.3),
379 a cardiac event (1.3 years, 0.3–2.7) and 85 a cerebrovascular
event (2.2 years, 1.2–3.2). The median follow-up of participants
who did not develop a cardiovascular event until the end of the
study was 4.8 (3.9–5.0) years. The major cardiovascular events
included 57 stroke cases (among which 52 were non-fatal), 19
deaths from cardiac origin, 56 non-fatal myocardial infarctions
and 14 sudden cardiac deaths. Cardiac events included 122
angioplasties, 51 myocardial infarctions, 45 cardiac arrhythmias,
40 coronary revascularisations and 40 cardiac interventions.
Cerebrovascular events included 52 non-fatal ischemic stroke
and 20 transient ischemic attacks.
Baseline characteristics
The mean baseline age of the participants was 61.6 (range:
41.9–81.2) years, and 80.6% of them were men. Regardless of the
outcome considered, patients who developed a cardiovascular
event more often had diabetes and were current smokers at
baseline (except for cardiac events, Table 1). Participants with
major cardiovascular events or with cardiac events had higher
plasma triglycerides, fasting plasma glucose and homocysteinae-
mia.
Baseline PFA and cardiovascular events
In bivariate analyses, stearidonic acid was lower in patients who
developed a cardiovascular event, regardless the event considered.
Total fatty acids were higher and arachidonic acid, total n–3
PUFA, DPA, DHA and the sum of EPA + DPA + DHA were
lower in patients who developed a major cardiovascular event
(Table 2). Arachidonic acid was lower in patients who developed a
cerebrovascular event.
In model 1, the risk of developing a major cardiovascular event
increased significantly in successive quartiles of total fatty acids
and decreased in successive quartiles of arachidonic acid, total n–3
PUFA, DPA, DHA, EPA + DHA and EPA + DPA + DHA
(Table 3). This inverse association was borderline significant with
increasing quartiles of stearidonic acid. The prevalence of major
cardiovascular events was lower in the third and fourth quartiles of
baseline plasma arachidonic acid (HR: 0.62, 0.40–0.96, p,0.03
and 0.51, 0.32–0.81, p,0.005 respectively) DPA (HR: 0.58, 0.37–
0.91, p,0.019 and 0.64, 0.40–1.00, p,0.05 respectively) and in
the fourth quartiles of baseline plasma DHA (p,0.001), EPA +
DHA (p,0.046) and EPA + DPA + DHA (p,0.029) respectively,
in comparison with the first quartile. Furthermore, the risk of
developing a cardiac event decreased with increasing quartiles of
stearidonic acid, EPA and DHA (Table 4). The risk of developing
a cerebrovascular event decreased with increasing quartiles of
arachidonic acid and stearidonic acid (Table 5).
In model 2, only stearidonic acid remained inversely associated
with the risk of developing a major cardiovascular event, a cardiac
event or a cerebrovascular event, while arachidonic acid was
inversely associated with the risk of cerebrovascular event.
Discussion
In this ancillary analysis which included patients with
established and treated CVDs, plasma stearidonic acid and
arachidonic acid showed protective effects on the recurrence of
CVD and cerebrovascular diseases, respectively. The associations
Table 4. Cont.
Plasma lipid profile HR Q1 HR Q2 HR Q3 HR Q4 P P for trend
DHA (C 22:6 n – 3)
Model 1 1.0 1.11 (0.84–1.47) 1.03 (0.77–1.37) 0.74 (0.55–1.00) 0.0480 0.049
Model 2 1.0 1.34 (0.97–1.86) 1.25 (0.87–1.76) 0.84 (0.58–1.21) 0.0206 0.249
EPA + DHA
Model 1 1.0 0.90 (0.68–1.18) 0.81 (0.61–1.08) 0.82 (0.61–1.08) 0.426 0.122
Model 2 1.0 1.14 (0.82–1.57) 1.01 (0.72–1.42) 0.92 (0.65–1.30) 0.643 0.500
EPA + DPA + DHA
Model 1 1.0 0.95 (0.72–1.26) 0.82 (0.61–1.09) 0.83 (0.62–1.10) 0.409 0.117
Model 2 1.0 1.21 (0.88–1.67) 1.02 (0.71–1.41) 0.93 (0.66–1.33) 0.412 0.464
N – 3/n – 6 ratio
Model 1 1.0 0.71 (0.53–0.94) 0.73 (0.55–0.96) 0.80 (0.60–1.05) 0.0566 0.127
Model 2 1.0 0.81 (0.59–1.12) 0.85 (0.61–1.17) 0.85 (0.62–1.17) 0.582 0.377
Model 1: adjusted for age, BMI, initial event, gender.
Model 2: adjusted for covariates in Model 1 + treatment allocation group (both placebos, B vitamin and placebo of omega 3, omega 3 and placebo of B vitamins, omega
3 and B vitamins),, tobacco smoking, alcohol consumption, systolic blood pressure, diabetes status, plasma cholesterol (HDL and LDL), triglycerides, total fatty acid
intake, n-3 supplementation and homocysteinemia.
doi:10.1371/journal.pone.0092548.t004
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Table 5. Multivariate hazard ratios (95% confidence intervals) showing the associations between baseline plasma lipid profile and
incident cerebrovascular events in the SU.FOL.OM3 study.
Plasma lipid profile HR Q1 HR Q2 HR Q3 HR Q4 P P for trend
Total fatty acids
Model 1 1.0 1.42 (0.73–2.79) 1.55 (0.80–3.00) 1.49 (0.77–2.91) 0.589 0.255
Model 2 1.0 0.47 (0.58–3.71) 1.61 (0.52–4.98) 1.27 (0.23–6.94) 0.691 0.621
Total SFA
Model 1 1.0 0.70 (0.39–1.26) 0.72 (0.40–1.30) 0.69 (0.38–1.26) 0.539 0.252
Model 2 1.0 0.71 (0.36–1.41) 0.85 (0.43–1.69) 0.53 (0.22–1.29) 0.496 0.246
Palmitic acid (C 16:0)
Model 1 1.0 0.86 (0.47–1.57) 0.85 (0.47–1.55) 0.83 (0.45–1.55) 0.932 0.578
Model 2 1.0 0.78 (0.38–1.61) 0.94 (0.46–1.90) 0.71 (0.29–1.72) 0.822 0.597
Trans fatty acids
Model 1 1.0 1.05 (0.59–1.87) 0.79 (0.41–1.49) 0.90 (0.49–1.65) 0.806 0.539
Model 2 1.0 0.93 (0.48–1.83) 0.67 (0.31–1.46) 1.02 (0.50–2.08) 0.721 0.820
Total MUFA
Model 1 1.0 1.84 (0.97–3.48) 1.24 (0.63–2.45) 1.93 (1.01–3.67) 0.127 0.141
Model 2 1.0 1.48 (0.71–3.05) 1.25 (0.58–2.67) 1.59 (0.67–3.82) 0.677 0.388
Oleic acid (C 18:1 n – 9)
Model 1 1.0 0.81 (0.43–1.51) 0.99 (0.55–1.77) 1.09 (0.61–1.95) 0.931 0.672
Model 2 1.0 0.78 (0.38–1.58) 0.74 (0.36–1.52) 0.79 (0.34–1.83) 0.847 0.505
Total PUFA
Model 1 1.0 0.81 (0.44–1.49) 1.02 (0.57–1.84) 0.85 (0.46–1.56) 0.840 0.782
Model 2 1.0 1.26 (0.56–2.85) 1.32 (0.55–3.18) 1.27 (0.50–3.27) 0.933 0.673
Total n-6 PUFA
Model 1 1.0 1.05 (0.57–1.93) 1.12 (0.62–2.03) 0.86 (0.46–1.62) 0.855 0.703
Model 2 1.0 1.00 (0.45–2.23) 1.22 (0.54–2.75) 1.05 (0.44–2.51) 0.948 0.826
Linoleic acid (C 18:2 n – 6)
Model 1 1.0 0.98 (0.54–1.77) 1.12 (0.62–2.01) 1.09 (0.59–2.01) 0.970 0.698
Model 2 1.0 0.93 (0.47–1.86) 0.64 (0.30–1.35) 1.03 (0.53–2.03) 0.624 0.789
Dihomo-U-linolenic acid (C 20:3 n – 6)
Model 1 1.0 0.96 (0.51–1.82) 1.11 (0.60–2.05) 1.35 (0.75–2.45) 0.675 0.275
Model 2 1.0 1.15 (0.51–2.59) 1.44 (0.66–3.13) 1.87 (0.88–3.98) 0.357 0.077
Arachidonic acid (C 20:4 n – 6)
Model 1 1.0 0.68 (0.39–1.16) 0.51 (0.28–0.92) 0.46 (0.24–0.86) 0.04 0.006
Model 2 1.0 0.69 (0.35–1.37) 0.52 (0.25–1.08) 0.44 (0.20–0.99) 0.18 0.033
Total n-3 PUFA
Model 1 1.0 1.04 (0.60–1.79) 0.69 (0.37–1.27) 0.69 (0.36–1.29) 0.37 0.125
Model 2 1.0 1.80 (0.94–3.46) 0.80 (0.36–1.77) 0.79 (0.35–1.77) 0.05 0.245
a-linolenic acid (C 18:3 n – 3)
Model 1 1.0 1.09 (0.62–1.93) 0.98 (0.54–1.77) 0.90 (0.49–1.68) 0.95 0.7
Model 2 1.0 0.95 (0.48–1.88) 0.87 (0.43–1.77) 0.94 (0.46–1.94) 0.98 0.80
Stearidonic acid (C 18:4 n – 3)
Model 1 1.0 0.90 (0.54–1.49) 0.43 (0.23–0.80) 0.44 (0.22–0.89) 0.014 0.002
Model 2 1.0 0.76 (0.41–1.40) 0.38 (0.18–0.82) 0.50 (0.23–1.08) 0.058 0.014
EPA (C 20:5 n – 3)
Model 1 1.0 1.08 (0.61–1.94) 1.14 (0.64–2.03) 0.83 (0.44–1.57) 0.78 0.68
Model 2 1.0 1.40 (0.69–2.82) 1.28 (0.63–2.61) 0.84 (0.37–1.91) 0.53 0.72
DPA (C 22:5 n – 3)
Model 1 1.0 0.86 (0.49–1.51) 0.83 (0.47–1.47) 0.62 (0.33–1.17) 0.54 0.16
Model 2 1.0 0.91 (0.45–1.83) 1.05 (0.54–2.05) 0.59 (0.26–1.31) 0.50 0.31
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between total PFA, total n–3 PUFA, EPA, DPA, DHA, EPA +
DHA, EPA + DPA + DHA and either major cardiovascular,
cardiac or cerebrovascular events seemed to be mediated by
established cardiovascular risks factors.
Numerous mechanistic studies have found that stearidonic acid
favourably compares with dietary EPA in side-by-side experi-
ments. Similar physiological effects were observed in ex vivo
platelet aggregation studies, changes in tissue arachidonic acid
content and eicosanoid formation, biomarkers of inflammation
and modification of plasma lipid profiles. However, no epidemi-
ological cohort study has tested the association between stearidonic
acid with CVD. Moreover, stearidonic acid concentration is very
low and at near the limit of detection, and dietary intakes is very
low, thus the implications from a nutritional standpoint may be
very limited. We also found evidence of an inverse association
between arachidonic acid and CVD. Several studies [19–21] have
shown an inverse association between plasma arachidonic acid
and risk of CVD, while others have shown either no association
[3,22]. Higher D5-desaturase index (a ratio of arachidonic to
dihomo c-linolenic ratio) has been reported to be associated with
higher insulin sensitivity [23,24], and lower incidence of the
metabolic syndrome [25] or CVD [26], which may partly explain
the inverse association between arachidonic acid and cardiovas-
cular events observed here. However, these results contrast with
other mechanistic studies revealing the prothrombotic and
proinflammatory properties of arachidonic acid, and merit further
exploration [27–30].
Our results suggest that associations with long chain n–3 PUFA
are mainly mediated by confounding factors. Contrary to our
findings, most [1,6,22,31,32], but not all [33–35] of the
observational cohort studies show an inverse association between
fish consumption, fish oil supplementation or plasma values of fish
derived long chain n–3 PUFA and CVDs. A meta-analysis of such
cohort studies [1] concluded that there was a modest evidence of
an inverse association between n–3 PUFA intake and CVD, with
no evidence of a linear dose-response relationship. Despite
adjustment for potential confounders, residual confounding is
likely to have occurred in some of these observational cohort
studies. Indeed, participants who consumed more PUFA were
more likely to be non-smokers [33,36–39], to be more physically
active [33,37,38], to take dietary vitamins [33], to eat more dietary
fibre, fruit and vegetables, and less saturated and trans fats [33],
and to drink less alcohol [33,37,38]. Not only did all these studies
not take into account such potential confounding factors, but also,
adjusting for these covariables does not fully protect against
residual confounding. Whether fish consumption provides other
beneficial nutrients not present in pure fish oil remains question-
able. The most recently published meta-analyses of randomized
controlled trials showed conflicting results regarding the effects of
fish oil or fish supplements on the occurrence of primary CVD.
Leon et al [8] reported on the effects of fish oil (EPA and DPA) on
mortality and arrhythmias from 12 studies including 32,779
patients. No beneficial effect on arrhythmic events or all-cause
mortality was reported but a significant reduction in deaths from
cardiac causes was found. Marik et al [9] identified 11 studies that
included 39,044 patients. They found that dietary supplementa-
tion with n–3 PUFA significantly reduced the risk of cardiovas-
cular deaths, sudden cardiac deaths, and non-fatal cardiovascular
events. With a total of 29 randomized controlled trials
(n = 35,144), with 25 of them concerning mortality and 14
restenosis, Filion et al [7] found that n–3 PUFA were not
associated with mortality or with restenosis, even though the
probability of some benefit remained high (0.93 and 0.90,
respectively). Of the total population included in these meta-
analyses, 20 to 35% were participants in the Gruppo Italiano per
lo Studio della Sopravvivenza nell’Intarto Miocardio (GISSI)-
Prevenzione trial [40]. In this trial, the treatment under
investigation was not blinded, and only a low or moderate
proportion of patients received modern intervention and medical
treatment. Also, only 5.0% of the patients had coronary
revascularisation at baseline, and only 4.7% were on cholesterol-
lowering drugs at hospital discharge. Therefore, it is not clear
whether the conclusions from these meta-analyses are still valid in
2011. Moreover, three doubled-blind randomized controlled trials
[15,18,41], not included in the previous meta-analyses, where
almost 20,000 patients participated for a median follow up over 4
years, failed to demonstrate a protective effect of n–3 PUFA
supplementation on the reduction of major cardiovascular events
Table 5. Cont.
Plasma lipid profile HR Q1 HR Q2 HR Q3 HR Q4 P P for trend
DHA (C 22:6 n – 3)
Model 1 1.0 1.06 (0.61–1.84) 0.65 (0.36–1.19) 0.64 (0.34–1.20) 0.22 0.070
Model 2 1.0 1.04 (0.52–2.09) 0.90 (0.44–1.86) 0.65 (0.29–1.47) 0.68 0.29
EPA + DHA
Model 1 1.0 0.93 (0.52–1.64) 0.86 (0.48–1.53) 0.68 (0.36–1.27) 0.67 0.23
Model 2 1.0 1.21 (0.60–2.41) 1.12 (0.54–2.31) 0.73 (0.33–1.63) 0.62 0.47
EPA + DPA + DHA
Model 1 1.0 0.98 (0.56–1.71) 0.79 (0.44–1.42) 0.63 (0.33–1.19) 0.47 0.12
Model 2 1.0 1.48 (0.75–2.91) 1.06 (0.51–2.23) 0.69 (0.30–1.60) 0.27 0.31
N – 3/n – 6 ratio
Model 1 1.0 0.88 (0.48–1.59) 1.15 (0.66–2.00) 0.65 (0.34–1.26) 0.37 0.41
Model 2 1.0 1.13 (0.57–2.25) 1.22 (0.62–2.42) 0.71 (0.32–1.57) 0.56 0.54
Model 1: adjusted for age, BMI, initial event, gender.
Model 2: adjusted for covariates in Model 1 + treatment allocation group (both placebos, B vitamin and placebo of omega 3, omega 3 and placebo of B vitamins, omega
3 and B vitamins),, tobacco smoking, alcohol consumption, systolic blood pressure, diabetes status, plasma cholesterol (HDL and LDL), triglycerides, total fatty acid
intake, n-3 supplementation and homocysteinemia.
doi:10.1371/journal.pone.0092548.t005
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in patients with personal history of CVD or prediabetes. The lack
of association between baseline PFA and subsequent cardiovascu-
lar events in our study as well as in these two randomised
controlled trials [15,18,41] could be due to an improvement in the
efficacy of cardioprotective drug treatments between the 1995–
1996 and 2006–2007 [42]. There been improvement in survival
but also the causes of death have shifted from CV to non-
cardiovascular origin [43]. Consequently, among patients who
have had a CVD but who are receiving good clinical care and are
at relatively low risk of future CV events, a beneficial effect of
habitual dietary intakes of fatty acids may be difficult to detect [44]
as illustrated by findings from the Omega trial [15].
The principal strength of this study is its large, well-character-
ized population with close to complete follow-up with respect to
clinical endpoints. Also, we adjusted for most traditional risks
factors, therapeutic parameters, and biomarkers characterizing
CVD. We evaluated not only the clinical effects of widely studied
long chains PUFA (EPA and DHA), but also the effects of a vast
majority of plasma fatty acids. Despite adjustment for potential
confounders, residual confounding is likely to have occurred in
that observational analysis. A major potential confounder is
engagement in physical activity, which was not available for our
participants at baseline. As subjects with high levels of physical
activity eat significantly more fish compared with their more
sedentary counterparts [33,37,38], it is likely that adjusting for
levels of physical activity might have reduced the association
between arachidonic acid or stearidonic acid and cardiovascular
outcomes.
In our population with established and well-treated history of
ischemic heart disease or stroke, the inverse association of long
chain n–3 PUFA with CVD was mainly driven by well-known
cardiovascular risk factors. These results, as the lack of impact of
our supplementation trial with DHA-EPA on CVD recurrence
[18], do not support the recommendations of use of n-3 PUFA for
the secondary prevention of CVD.
Supporting Information
Checklist S1 CONSORT Checklist.
(DOC)
Acknowledgments
We thank the health professionals, staff at the coordinating centre and
study centres as well as patients who participated in the SU.FOL.OM3
trial. We wish to thank Fabien Szabo de Edelenyi and Laurent Bourhis for
their assistance with the database preparation.
Author Contributions
Conceived and designed the experiments: SH PG. Performed the
experiments: SH PG. Analyzed the data: LKF. Contributed reagents/
materials/analysis tools: SH PG FL LKF. Wrote the paper: LKF. Assisted
with the interpretation of data and read and edited each draft of the
manuscript for important intellectual content: FL EKG VAA JB PG SH.
Read and approved the final manuscript: FL EKG VAA JB PG SH.
References
1. Mente A, de Koning L, Shannon HS, Anand SS (2009) A systematic review of
the evidence supporting a causal link between dietary factors and coronary heart
disease. Arch Intern Med 169: 659–669.
2. He K (2009) Fish, long-chain omega-3 polyunsaturated fatty acids and
prevention of cardiovascular disease–eat fish or take fish oil supplement? Prog
Cardiovasc Dis 52: 95–114.
3. Harris WS, Poston WC, Haddock CK (2007) Tissue n-3 and n-6 fatty acids and
risk for coronary heart disease events. Atherosclerosis 193: 1–10.
4. Lee SH, Shin MJ, Kim JS, Ko YG, Kang SM, et al. (2009) Blood
eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause
mortality in patients with acute myocardial infarction–data from Infarction
Prognosis Study (IPS) Registry. Circ J 73: 2250–2257.
5. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, et al. (2003) n-3
Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal
myocardial infarction in older adults: the Cardiovascular Health Study.
Am J Clin Nutr 77: 319–325.
6. Sun Q, Ma J, Campos H, Rexrode KM, Albert CM, et al. (2008) Blood
concentrations of individual long-chain n-3 fatty acids and risk of nonfatal
myocardial infarction. Am J Clin Nutr 88: 216–223.
7. Filion KB, El Khoury F, Bielinski M, Schiller I, Dendukuri N, et al. (2010)
Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of
randomized controlled trials. BMC Cardiovasc Disord 10: 24.
8. Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, et al. (2008)
Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 337:
a2931.
9. Marik PE, Varon J (2009) Omega-3 dietary supplements and the risk of
cardiovascular events: a systematic review. Clin Cardiol 32: 365–372.
10. Saravanan P, Davidson NC, Schmidt EB, Calder PC (2010) Cardiovascular
effects of marine omega-3 fatty acids. Lancet 376: 540–550.
11. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, et al.
(2004) Omega 3 fatty acids for prevention and treatment of cardiovascular
disease. Cochrane Database Syst Rev: CD003177.
12. Bucher HC, Hengstler P, Schindler C, Meier G (2002) N-3 polyunsaturated fatty
acids in coronary heart disease: a meta-analysis of randomized controlled trials.
Am J Med 112: 298–304.
13. Plourde M, Cunnane SC (2007) Extremely limited synthesis of long chain
polyunsaturates in adults: implications for their dietary essentiality and use as
supplements. Appl Physiol Nutr Metab 32: 619–634.
14. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, et al. (2006) n-3
Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit
cardiovascular disease outcomes in primary- and secondary-prevention studies: a
systematic review. Am J Clin Nutr 84: 5–17.
15. Kromhout D, Giltay EJ, Geleijnse JM (2010) n-3 fatty acids and cardiovascular
events after myocardial infarction. N Engl J Med 363: 2015–2026.
16. Arab L (2003) Biomarkers of fat and fatty acid intake. J Nutr 133 Suppl 3: 925S–
932S.
17. Overby NC, Serra-Majem L, Andersen LF (2009) Dietary assessment methods
on n-3 fatty acid intake: a systematic review. Br J Nutr 102 Suppl 1: S56–63.
18. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, et al. (2010)
Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a
randomised placebo controlled trial. BMJ 341: c6273.
19. Salonen JT, Salonen R, Penttila I, Herranen J, Jauhiainen M, et al. (1985)
Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the
risk of death from coronary artery disease. Am J Cardiol 56: 226–231.
20. Wang L, Folsom AR, Eckfeldt JH (2003) Plasma fatty acid composition and
incidence of coronary heart disease in middle aged adults: the Atherosclerosis
Risk in Communities (ARIC) Study. Nutr Metab Cardiovasc Dis 13: 256–266.
21. Yamagishi K, Nettleton JA, Folsom AR (2008) Plasma fatty acid composition
and incident heart failure in middle-aged adults: the Atherosclerosis Risk in
Communities (ARIC) Study. Am Heart J 156: 965–974.
22. Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, et al. (2011)
Relationships between plasma fatty acid composition and coronary artery
disease. J Atheroscler Thromb 18: 99–107.
23. Borkman M, Storlien LH, Pan DA, Jenkins AB, Chisholm DJ, et al. (1993) The
relation between insulin sensitivity and the fatty-acid composition of skeletal-
muscle phospholipids. N Engl J Med 328: 238–244.
24. Vessby B, Tengblad S, Lithell H (1994) Insulin sensitivity is related to the fatty
acid composition of serum lipids and skeletal muscle phospholipids in 70-year-
old men. Diabetologia 37: 1044–1050.
25. Warensjo E, Riserus U, Vessby B (2005) Fatty acid composition of serum lipids
predicts the development of the metabolic syndrome in men. Diabetologia 48:
1999–2005.
26. Ohrvall M, Berglund L, Salminen I, Lithell H, Aro A, et al. (1996) The serum
cholesterol ester fatty acid composition but not the serum concentration of alpha
tocopherol predicts the development of myocardial infarction in 50-year-old
men: 19 years follow-up. Atherosclerosis 127: 65–71.
27. Bays HE, Tighe AP, Sadovsky R, Davidson MH (2008) Prescription omega-3
fatty acids and their lipid effects: physiologic mechanisms of action and clinical
implications. Expert Rev Cardiovasc Ther 6: 391–409.
28. Czernichow S, Thomas D, Bruckert E (2010) n-6 Fatty acids and cardiovascular
health: a review of the evidence for dietary intake recommendations. Br J Nutr
104: 788–796.
29. Harris W (2010) Omega-6 and omega-3 fatty acids: partners in prevention. Curr
Opin Clin Nutr Metab Care 13: 125–129.
30. Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ, Klungel OH, et al. (2012)
Effects of n-3 fatty acids on major cardiovascular events in statin users and non-
users with a history of myocardial infarction. Eur Heart J.
Plasma FA and CV Risk in Secondary Prevention
PLOS ONE | www.plosone.org 10 April 2014 | Volume 9 | Issue 4 | e92548
31. Aarsetoey H, Ponitz V, Grundt H, Staines H, Harris WS, et al. (2009) (n-3) Fatty
acid content of red blood cells does not predict risk of future cardiovascular
events following an acute coronary syndrome. J Nutr 139: 507–513.
32. Mozaffarian D, Rimm EB (2006) Fish intake, contaminants, and human health:
evaluating the risks and the benefits. JAMA 296: 1885–1899.
33. Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC (1995)
Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary
disease among men. N Engl J Med 332: 977–982.
34. Manger MS, Strand E, Ebbing M, Seifert R, Refsum H, et al. (2010) Dietary
intake of n-3 long-chain polyunsaturated fatty acids and coronary events in
Norwegian patients with coronary artery disease. Am J Clin Nutr 92: 244–251.
35. Oomen CM, Ocke MC, Feskens EJ, Kok FJ, Kromhout D (2001) alpha-
Linolenic acid intake is not beneficially associated with 10-y risk of coronary
artery disease incidence: the Zutphen Elderly Study. Am J Clin Nutr 74: 457–
463.
36. Egeland GM, Meyer HE, Selmer R, Tverdal A, Vollset SE (2001) Cod liver oil
consumption, smoking, and coronary heart disease mortality: three counties,
Norway. Int J Circumpolar Health 60: 143–149.
37. Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE (2003) Fish and long-
chain omega-3 fatty acid intake and risk of coronary heart disease and total
mortality in diabetic women. Circulation 107: 1852–1857.
38. Meyer KA, Kushi LH, Jacobs DR Jr, Folsom AR (2001) Dietary fat and
incidence of type 2 diabetes in older Iowa women. Diabetes Care 24: 1528–
1535.
39. Rissanen T, Voutilainen S, Nyyssonen K, Lakka TA, Salonen JT (2000) Fish oil-
derived fatty acids, docosahexaenoic acid and docosapentaenoic acid, and the
risk of acute coronary events: the Kuopio ischaemic heart disease risk factor
study. Circulation 102: 2677–2679.
40. (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin
E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 354:
447–455.
41. Investigators OT, Bosch J, Gerstein HC, Dagenais GR, Diaz R, et al. (2012) n-3
fatty acids and cardiovascular outcomes in patients with dysglycemia.
N Engl J Med 367: 309–318.
42. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, et al. (2009)
Cardiovascular prevention guidelines in daily practice: a comparison of
EUROASPIRE I, II, and III surveys in eight European countries. Lancet
373: 929–940.
43. Roger VL, Weston SA, Gerber Y, Killian JM, Dunlay SM, et al. (2010) Trends
in incidence, severity, and outcome of hospitalized myocardial infarction.
Circulation 121: 863–869.
44. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H (2012) Fish oil and omega-
3 fatty acids in cardiovascular disease: do they really work? Eur Heart J 33: 436–
443.
Plasma FA and CV Risk in Secondary Prevention
PLOS ONE | www.plosone.org 11 April 2014 | Volume 9 | Issue 4 | e92548
